IP Library Granted Patent US 9,856,317
Granted Patent B2
US 9,856,317 · App. 15/058,612 · Granted Jan 2, 2018

Human antibody molecules for IL-13

Inventors: Phillip David Monk (Cambridge, GB); Lutz Jermutus (Cambridge, GB); Celia Patricia Shorrock (Noyarey, FR); Ralph Raymond Minter (Cambridge, GB)
Assignee: MEDIMMUNE LIMITED
C07K16/244A61K2039/505C07K2317/21C07K2317/565C07K2317/622C07K2317/73C07K2317/76C07K2317/92Y10S514/826Y10S514/883
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,856,317
App. No.
15/058,612
Granted
Jan 2, 2018
Kind
B2
Abstract

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Claims (25)

1. An isolated nucleic acid molecule comprising a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds human interleukin-13 (IL-13), wherein the antibody or antigen-binding fragment thereof comprises a set of complementarity determining regions (CDRs) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3, wherein:

HCDR1 comprises SEQ ID NO:7;

HCDR2 comprises SEQ ID NO:8;

HCDR3 comprises SEQ ID NO:9;

LCDR1 comprises SEQ ID NO:10;

LCDR2 comprises SEQ ID NO:11; and

LCDR3 comprises SEQ ID NO:12.

2. The nucleic acid molecule according to claim 1 , wherein the nucleic acid molecule is operably linked to a control sequence.

3. A vector comprising the nucleic acid molecule according to claim 2 .

4. A host cell transformed with the vector of claim 3 .

5. The host cell of claim 4 , wherein the host cell is a mammalian host cell.

6. The mammalian host cell of claim 5 , wherein the host cell is a Chinese hamster ovary (CHO) cell, a HeLa cell, a baby hamster kidney cell, a NS0 mouse melanoma cell, a YB2/0 rat myeloma cell, a human embryonic kidney cell, or a human embryonic retina cell.

7. A method of making an antibody or antigen-binding fragment thereof that binds human interleukin-13 (IL-13) comprising culturing a host cell according to claim 4 under suitable conditions for producing the antibody or antigen-binding fragment thereof.

8. The method of claim 7 further comprising isolating the antibody or antigen-binding fragment thereof secreted from the host cell.

9. An isolated nucleic acid molecule comprising a polynucleotide encoding an antibody or antigen-binding fragment thereof that binds human interleukin-13 (IL-13), wherein the antibody or antigen-binding fragment thereof comprises the BAK502G9 heavy chain variable region (SEQ ID NO: 15) and the BAK502G9 light chain variable region (VL) (SEQ ID NO:16).

10. The nucleic acid molecule according to claim 9 , wherein the nucleic acid molecule is operably linked to a control sequence.

11. A vector comprising the nucleic acid molecule according to claim 10 .

12. A host cell transformed with the vector of claim 11 .

13. The host cell of claim 12 , wherein the host cell is a mammalian host cell.

14. The mammalian host cell of claim 13 , wherein the host cell is a Chinese hamster ovary (CHO) cell, a HeLa cell, a baby hamster kidney cell, a NS0 mouse melanoma cell, a YB2/0 rat myeloma cell, a human embryonic kidney cell, or a human embryonic retina cell.

15. A method of making an antibody or antigen-binding fragment thereof that binds human interleukin-13 (IL-13) comprising culturing a host cell according to claim 12 under suitable conditions for producing the antibody or antigen-binding fragment thereof.

16. The method of claim 15 further comprising isolating the antibody or antigen-binding fragment thereof secreted from the host cell.

17. An isolated nucleic acid molecule comprising SEQ ID NO:111 or SEQ ID NO:112.

18. A host cell transformed with the nucleic acid molecule of 17 .

19. The host cell of claim 18 , wherein the host cell is a Chinese hamster ovary (CHO) cell, a HeLa cell, a baby hamster kidney cell, a NS0 mouse melanoma cell, a YB2/0 rat myeloma cell, a human embryonic kidney cell, or a human embryonic retina cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2016
From: MONK, PHILLIP DAVID; JERMUTUS, LUTZ ULRICH JOCHEN WILHELM; MINTER, RALPH RAYMOND; SHORROCK, CELIA PATRICIA
To: CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
Reel/Frame 038857/0001 →
CHANGE OF NAME Recorded Jun 9, 2016
From: CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
To: MEDIMMUNE LIMITED
Reel/Frame 038943/0145 →
Priority Claims (1)
GB 0407315.1 · Mar 31, 2004 · national
Continuity (6)
Division 12941677 · Nov 8, 2010
Division 10564647
Provisional Application 60487512 · Jul 15, 2003
Provisional Application 60558216 · Mar 31, 2004
Provisional Application 60573791 · May 24, 2004
Related Publication 20160280779A1 · Sep 29, 2016